HomeCompareTOUS vs JNJ

TOUS vs JNJ: Dividend Comparison 2026

TOUS yields 1.74% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TOUS wins by $2.2K in total portfolio value
10 years
TOUS
TOUS
● Live price
1.74%
Share price
$34.54
Annual div
$0.60
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.2K
Annual income
$194.46
Full TOUS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TOUS vs JNJ

📍 TOUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTOUSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TOUS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TOUS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TOUS
Annual income on $10K today (after 15% tax)
$147.70/yr
After 10yr DRIP, annual income (after tax)
$165.29/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $538.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TOUS + JNJ for your $10,000?

TOUS: 50%JNJ: 50%
100% JNJ50/50100% TOUS
Portfolio after 10yr
$21.1K
Annual income
$511.12/yr
Blended yield
2.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TOUS
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TOUS buys
0
JNJ buys
0
No recent congressional trades found for TOUS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTOUSJNJ
Forward yield1.74%3.36%
Annual dividend / share$0.60$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$22.2K$20.0K
Annual income after 10y$194.46$827.78
Total dividends collected$1.8K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TOUS vs JNJ ($10,000, DRIP)

YearTOUS PortfolioTOUS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,874$173.77$10,676$355.77+$198.00TOUS
2$11,812$176.59$11,407$389.39+$405.00TOUS
3$12,818$179.27$12,198$426.53+$620.00TOUS
4$13,897$181.81$13,056$467.62+$841.00TOUS
5$15,054$184.23$13,987$513.12+$1.1KTOUS
6$16,294$186.51$14,998$563.56+$1.3KTOUS
7$17,623$188.67$16,098$619.52+$1.5KTOUS
8$19,047$190.71$17,295$681.69+$1.8KTOUS
9$20,573$192.64$18,599$750.82+$2.0KTOUS
10$22,208$194.46$20,022$827.78+$2.2KTOUS

TOUS vs JNJ: Complete Analysis 2026

TOUSStock

The fund seeks to provide long-term capital growth.

Full TOUS Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TOUS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TOUS vs SCHDTOUS vs JEPITOUS vs OTOUS vs KOTOUS vs MAINTOUS vs ABBVTOUS vs MRKTOUS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.